On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.
Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.
The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.
On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.
Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.
it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.
As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.
Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.
It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.
It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.
Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.
Credit: AI Image
The International Agency for Research on Cancer (IARC), the World Health Organization's (WHO) cancer research agency, has classified three widely used medicines—hydrochlorothiazide, voriconazole, and tacrolimus—as Group 1 carcinogens, meaning they are "carcinogenic to humans."
All three medicines are included on the WHO Model List of Essential Medicines and are prescribed to millions of people worldwide for treating hypertension, serious fungal infections, and preventing organ transplant rejection.
A Group 1 classification means there is sufficient scientific evidence that an agent can cause cancer in humans under certain circumstances. However, it does not indicate how likely a person is to develop cancer while taking the medicine as prescribed. The actual risk depends on factors such as the dose, duration of use, individual health, and other risk factors.
Hydrochlorothiazide: It is a thiazide diuretic commonly prescribed to treat essential hypertension. Although newer blood pressure medications are increasingly used, it remains a widely prescribed treatment because of the global burden of hypertension.
Voriconazole: It is a broad-spectrum triazole antifungal medicine used to treat invasive aspergillosis and other serious fungal infections, particularly among transplant recipients and other immunocompromised patients.
Tacrolimus: It is an immunosuppressive medicine used to reduce the risk of organ rejection in adult and pediatric transplant recipients and to prevent graft-versus-host disease following stem cell transplantation. Topical tacrolimus is also used as a second-line treatment for atopic dermatitis and vitiligo when topical corticosteroids are unsuitable.
Also read: Ancient Inca DNA Reveals Smallpox Reached Americas Through European Colonization
"The IARC Monographs Working Group reviewed evidence from epidemiological studies, cancer bioassays in experimental animals, and mechanistic studies to assess the carcinogenic hazard to humans of exposure to these agents and concluded that hydrochlorothiazide, tacrolimus, and voriconazole are all carcinogenic to humans (Group 1)," the IARC said.
Dr. Shyam Aggarwal, Chairman, Medical Oncology, Sir Ganga Ram Hospital, told HealthandMe that the classification identifies a cancer hazard, not the level of cancer risk associated with normal therapeutic use.
"The IARC underlines that this Group 1 listing identifies a cancer hazard—the potential of an agent to cause malignancy rather than measuring how great the actual risk is when the medicines are taken at normal therapeutic doses. All three remain listed as essential medicines by WHO, reflecting their critical role in treating serious illness," he said.
Read More: Breastfeeding Can Help Reduce Mothers' Risk of Type 2 Diabetes, Breast Cancer and More
Dr. Aggarwal stressed that patients should not stop taking these medicines without consulting their doctor.
"Abruptly stopping any of these agents can result in dangerous rises in blood pressure, uncontrolled infection, or transplant failure. The recommended course is to speak with the treating physician, adopt rigorous sun-protection habits if taking hydrochlorothiazide or voriconazole, and maintain regular surveillance for those receiving tacrolimus after transplantation," he added.
Dr. Tushar Tayal, Associate Director – Internal Medicine, CK Birla Hospital, Gurugram, told HealthandMe the reclassification should not be a cause for alarm.
According to him, the concern relates to long-term cumulative exposure rather than a single dose. Stopping treatment abruptly could pose a much greater immediate risk, including uncontrolled hypertension, severe infection, or transplant rejection.
Credit: AI
A UK-based surgeon from Egypt has been permanently barred from practising medicine after a medical tribunal found that he made a catastrophic blunder during an emergency bowel surgery.
Dr Yasser Adly Abdel Rahman, who was working as a locum surgeon at Royal Oldham Hospital in Greater Manchester, mistakenly connected the wrong parts of a patient’s digestive system, a procedure experts described as “not known to man.”
Dr Rahman carried out the operation on a young man in August 2020. Instead of restoring the patient’s bowel, the surgery created a “closed loop” that caused contents of the bowel to flow back into the stomach.
The error left the patient in unimaginable pain and in a condition deemed “not compatible with life.”
According to findings by the Medical Practitioners Tribunal Service (MPTS), the patient was left feeling severe pain, vomiting and an inability to pass stool after the surgery.
A second surgeon later performed emergency corrective surgery, creating a stoma and saved the patient’s life.
The tribunal heard that Dr Rahman failed to realise the seriousness of the patient’s deteriorating condition and did not adequately respond to concerns raised by the patient’s family and medical colleagues.
An expert from the General Medical Council (GMC) described the erroneous procedure as “as bad as it gets” and said the surgical connection was “not known to man.”
Also read: The Rise of Robotic Joint Replacement: How Technology Is Transforming Orthopaedic Surgery
The tribunal ruled that Dr Rahman’s actions amounted to serious professional misconduct.
It also found that, in 2021, after restrictions were placed on his medical practice, he breached them by taking up a locum job in Affidea Express Care Clinic in Ireland in 2022.
Dr Rahman was absent at the misconduct hearing and instead maintained that he was a victim of a witch hint and had been made a “scapegoat.”
But, the tribunal concluded that his incompetence, failure to accept responsibility and repeated breaches of regulatory conditions meant he posed an ongoing risk to patients. He has now been permanently removed from the UK medical register.
A closed loop bowel obstruction occurs when a section of the intestine is blocked at two points, restricting its contents. This can fatally cut off blood supply to the bowel, causing tissue death, perforation, infection and sepsis if not treated urgently.
In this case, the incorrect surgical connections diverted bowel contents back into the patient’s stomach instead of allowing them to pass normally through the digestive tract, creating a life-threatening emergency that required immediate corrective surgery.
While surgical complications can occur even in experienced hands, medical experts told the tribunal this error was far from acceptable.
The case has also drawn attention because the surgeon allegedly ignored warning signs after the operation. He later breached restrictions placed on his medical licence by taking up a job elsewhere. These factors ultimately contributed to the decision to strike him off from the UK register permanently.
Also read: UK Woman Becomes World-First To Receive Experimental Cell Therapy For Ovarian Cancer
Dr Rahman qualified in 1993 from Ain Shams University in Cairo, Egypt. He trained as a general and colorectal surgeon.
He later worked in the UK as a locum consultant, meaning he was employed on temporary contracts rather than in a permanent consultant position.
At the time of the incident in August 2020, he had only been working at Royal Oldham Hospital in Greater Manchester for a few days before performing the emergency bowel surgery.
Credit: iStock
After several months of a statewide crackdown on food adulteration, Maharashtra has now banned the manufacture and sale of non-dairy paneer, commonly known as analogue paneer or analogue cottage cheese.
The move follows multiple raids on fake paneer manufacturing units and the seizure of large quantities of spurious dairy products.
Earlier this week, the Chhattisgarh government also banned the sale and use of analogue paneer across the state. The Health Department announced that the product will no longer be permitted in markets, hotels, restaurants or roadside eateries. Maharashtra has now become the second Indian state to impose such a ban.
The order, issued by Food Safety Commissioner Tukaram Mundhe in Maharashtra, prohibits the manufacture, processing, packing, storage, transportation, wholesale and retail sale, distribution, and offering for sale of analogue or non-dairy paneer across the state.
Violations can attract up to six months' imprisonment and a fine of Rs 1 lakh under the Food Safety and Standards Act, 2006.
In cases where the consumption of unsafe food results in death, the law provides for life imprisonment and a minimum fine of Rs 10 lakh.
As per the Maharashtra Maharashtra Food and Drug Administration (FDA), strict legal action will also be taken against individuals or establishments selling analogue paneer as genuine dairy paneer for misleading consumers.
The decision follows findings from the Maharashtra FDA's year-long enforcement and surveillance drive.
According to the regulator, routine inspections, food sampling and awareness campaigns failed to curb the sale of analogue paneer.
"The proportion of non-conforming samples remained persistently high at 35.4 per cent of the samples analysed," the FDA order stated. Between April 1, 2025, and March 31, 2026, the FDA collected paneer and analogue paneer samples from across the state.
Further, the FDA stated that its year-long inspections found that hotels, restaurants, caterers and other food establishments were routinely using analogue paneer instead of genuine paneer without informing customers through menus, invoices or display boards.
Authorities also found that analogue paneer was often transported and sold without original packaging, mandatory labels, invoices, batch identification or traceability documents, making it difficult to identify its source and increasing risks to public health.
Traditional paneer is a fresh, soft, non-melting cheese commonly used in Indian cuisine. It is made by curdling milk with acidic ingredients such as lemon juice, vinegar, or citric acid, separating the curd from the whey. The curds are then drained and pressed to remove excess water.
On the other hand, analogue paneer is made using vegetable fats or oils, starches and other non-dairy ingredients instead of milk fat.
As per the Food Safety and Standards Authority of India (FSSAI) regulations:
FSSAI and experts recommend these simple checks:
Health experts warn that adulterated paneer can pose serious health risks, especially if manufactured using unsafe ingredients.
Possible risks include:
© 2024 Bennett, Coleman & Company Limited